Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?The Motley Fool • 10/22/26
Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?Zacks Investment Research • 10/21/26
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/20/26
Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Inches Higher24/7 Wall Street • 10/20/26
Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026Business Wire • 10/19/26
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/17/26
Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know24/7 Wall Street • 10/16/26
These 4 Dividend Stocks Passed the 2020 Stress Test. Are They Buys in Now October?24/7 Wall Street • 10/14/26
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research • 10/14/26
Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/13/26
Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industryWSJ • 10/13/26
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma banBusiness Insider • 10/13/26
‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocksMarket Watch • 10/13/26
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market TodayZacks Investment Research • 10/12/26
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 10/12/26
Bristol Myers Scores Two Phase 3 Wins, But A Key Rival Plummets On OneInvestors Business Daily • 10/12/26
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETsBusiness Wire • 10/12/26
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary EndpointBusiness Wire • 10/12/26